Topical oxygen therapy is a cosmetic procedure that is becoming more and more popular in dermatology. Oxygen infusions provided by devices such as the X2 Exea (Exea, Castello d'Argile, Italy) allow flows of pure oxygen (up to 96% purity) to reach the superficial layer of the skin and to be absorbed by the dermis and the epidermis.
AAG is a hereditary thinning of the hair induced by the effects of androgenetic hormones on the follicles of hair in genetically susceptible men and women. Hair follicles become smaller, producing shorter and thinner hair. Currently no definitive therapies are available for the treatment of AAG and TE [8] . These pathologies affect about 70% of men and 40% of women at a certain stage of their lives. Men typically present with a recession of the attachment of hair at the temples and hair loss at the crown, while the women normally have a widespread thinning on all the top of the scalp. Both genetic and environmental issues play a role, and definitive etiologies remain unknown [9] . The treatment methods currently available vary from the use of non-pharmacological therapies such as the use of supplements, amino acids, and other essential elements [10] . Pharmacological therapies include minoxidil, finasteride, phytosterols, low doses of corticosteroids, estroprogestinic therapy, and antiandrogenic drugs [11] . Vehiculated oxygen therapy has been used in medicine to improve cellular metabolism, accelerate the healing process, and reduce irritation. Additionally, it has anti-inflammatory and antibacterial effects.
Thirty patients with AAG and telogen effluvium were enrolled and randomized into 3 treatment groups:
• Group A was treated daily with 5% minoxidil 3 times per week in monotherapy for 16 weeks with follow-up at 8 weeks after finishing the therapy.
• Group B was treated with 5% minoxidil administered every other day (topical) and oxygen delivery with the X2 Exea device) in sessions lasting 30 minutes for 16 weeks with follow-up at 8 weeks after finishing treatment.
• Group C started treatment with a phytotherapeutic agent (composed of Zingiber officinale, Salvia officinalis, Cuscuta epithymum, Carum petroselinum, and Capsicum annuum) administered with the traditional topical application alternating with oxygen infusion with the X2 Exea device in sessions lasting 30 minutes for 16 weeks with follow-up at 8 weeks after stopping treatment. The rationale for the phytotherapeutic drug's components was to intervene in several targets of the pilosebaceous unit: to increase blood flow, decrease local inflammatory state, decrease local PH, check for excessive bacterial growth, and to have moisturizing, emollient action on the hair.
The study parameters were:
• Objective and dermatoscopic examination of the hair
• Hair count
• Evaluation of the stage of AAG classified according to the scale of Norwood and Ludwig derma gangrenosum, hidradenitis suppurativa, burns, skin grafts, and others [2] . Hyperbaric oxygen therapy was also proposed as a skin rejuvenation and antiaging treatment [3] .
Oxygen has various beneficial effects on the skin. It is capable of improving cellular metabolism, of accelerating the healing processes, of reducing skin irritations, and of producing an anti-inflammatory effect [4] . Oxygen is also able to produces a neoangiogenic effect [5] . In fact, it promotes the release of vascular endothelial growth factor (VEGF) and other factors involved in neoangiogenesis [4] . Oxygen also has an antibacterial effect thanks to its ability to release reactive oxygen species (ROS), compounds that are extremely toxic, as they degrade cellular membranes and cause death of the pathogenic microorganisms [6] .
However, the use of oxygen infusion therapy is not readily found in the medical literature. Few, if any, articles describe the use of oxygen infusion therapy in dermatologic diseases and their effectiveness, although these kinds of infusions are widely used.
Our group attempted to evaluate the effectiveness of oxygen infusion therapy in association with traditional drugs in the treatment of diseases that cause hair loss (androgenetic alopecia and telogen effluvium), mild acne, moderate acne, and chronic inflammatory dermatologic diseases. Four studies were conducted. In the first, the objective of the study was to evaluate the greater therapeutic efficacy of 5% minoxidil carried by an oxygen dispenser compared to the traditional method of topical application. A second comparison was made between minoxidil and a phytotherapeutic agent consisting of capsicum A, ginseng, sage and Cathamus tinctorius carried by an oxygen dispenser. In the second study the objective was to evaluate the effectiveness of topical oxygen therapy in mild acne and to compare the local administration of 96% pure oxygen to the use of a phytotherapeutic drug and a local oxygen administration therapy. In the third study patients with moderate acne were treated with topical clindamycin and oxygen infusion therapy. In the fourth study patients with psoriasis or atopic dermatitis were treated with topical medication (vitamin D derivatives for psoriasis and corticosteroid for atopic dermatitis) and local oxygen therapy.
Methods

Topical Oxygen Therapy and Diseases that Cause Hair Loss
Androgenetic male or female alopecia (AAG) and telogen effluvium (TE) are the most common forms of non-scarring alopecia. They affect men and women of all ages and remain an unresolved therapeutic problem.
Telogen effluvium is a very intense hair loss that causes thinning of the hair without the appearance of glabrous patches. The causes can be multiple, the most frequent being groups. The diagnostic dermoscopic tool used to evaluate acne was the DL4 Dermlite (3Gen, San Juan Capistrano, 
Topical Oxygen Therapy and Mild Acne
A second study was conducted to evaluate the effectiveness of oxygen therapy in the treatment of mild acne vulgaris and effectiveness of the same treatment in conjunction with a sebo-regulating phytotherapeutic drug.
Acne is an inflammatory chronic dermatosis [12] with a multifactorial etiology [13] that mainly affects teenagers and young adults [14] . It is characterized by a remarkable lesional polymorphism due to the presence of both noninflammatory (open and closed comedones) and inflammatory cutaneous elements (papules, pustules and nodules), located in the seborrheic areas of the face and trunk. Acne is one of the dermatologic conditions with the greater impact on social life [15] . The main goal of the treatment is to prevent the extension of the inflammation to the deep tissue structures and the consequent appearance of scars [16] . Topical treatments currently available for the treatment of mild acne are topical retinoids and their derivatives are benzoyl peroxide, topical antibiotics, and azelaic acid [17] .
Twenty subjects were enrolled, 9 males and 11 females, aged between 19 and 66 years old (median age 32.3) affected by acne vulgaris of mild degree, randomized into 2 treatment and favors its penetration. Sessions performed 3 times per week also considerably reduced the quantity of drugs that would otherwise be applied daily for months, risking drug resistance of Propionibacterium.
Topical Oxygen Therapy and Inflammatory Dermatological Lesions
The patients who participated in this study had suspended previous treatments of their respective dermatological diseases for at least 4 weeks to the study. They participated in treatments with safe and effective topical therapies in liquid formulation, which were applied during oxygen delivery. A derivative of vitamin D was used for psoriasis (calcipotriol lotion 50 µg per 1 mL) and a low-potency steroid (hydrocortisone butyrate 0.1% lotion) was used for atopic dermatitis. 
Vehiculated Oxygen Therapy and Moderate Acne
Eighteen patients suffering from acne on the face of moderate degree were selected for this study (10 females and 8 males; mean age 23 years). The patients showed typical papulopustular lesions; the average number of lesions on the face before treatment was 21.9. All the patients had suspended previous acne treatments for at least 4 weeks prior to the study.
Liquid formulations were applied during oxygen delivery.
The session consisted of the application of clindamycin 1% lotion 3 times per week for about 30 minutes, followed by oxygen infusion therapy.
In between treatments, the patients applied a moisturizing base cream without active ingredients (Cetaphil, Galderma Laboratories, Fort Worth, TX) after washing morning and evening.
In our study, the patients participated 3 sessions of oxygen therapy per week for a total of 12 sessions, and progress, safety, and effectiveness were evaluated before, during (6 sessions, 2 weeks) and after treatment (12 sessions, 4 weeks). All patients showed an improvement in terms of number of typical papulopustular lesions. The initial average number of lesions was 21.9. After 1 week it was reduced to 8.7, after 2 weeks it was 3.7 and at the end of treatment was 3.1. The lesions were also evaluated at a followup 1 and 3 months after treatment (the average number of lesions being 3.2 and 3.9 respectively), showing maintenance of total or partial results.
The combination of oxygen therapy with clindamycin, in our opinion, enhances the effect of topical antibiotic therapy In the future, more studies will certainly be needed to support the results obtained and to extend this technology to other dermatological indications.
Conclusions
Topical oxygen therapy was useful in the treatment of hair loss conditions (such androgenetic alopecia or telogen effluvium), in the treatment of mild and moderate acne, and in the treatment of chronic cutaneous diseases. Topical oxygen therapy showed its effectiveness as a support therapy in all the diseases and therefore should be offered as a possible therapeutic treatment to the patient. Infusions of phytotherapeutic drugs and minoxidil via the X2 Exea oxygen dispenser, according to our studies, seem to improve the effectiveness of the drugs in both hair loss conditions and mild acne. Topical oxygen therapy should be proposed as an adjuvant therapy in the treatment of these conditions. Other studies should be done to evaluate the effectiveness of topical oxygen therapy as an adjuvant therapy in larger study groups.
